Table 1.
Frequency of GNA alterations in cancers.
| Cancers | GNAS | |||||
|---|---|---|---|---|---|---|
| Alteration | Mutation | Fusion | Amplification | Deep deletion | Multiple Alterations | |
| Colorectal | 11.45% of 594 cases | 3.87% (23 cases) | 0.17% (1 case) | 7.24% (43 cases) | 0.17% (1 case) | |
| Stomach | 9.55% of 400 cases | 5.45% (24 cases) | 3.64% (16 cases) | 0.23% (1 case) | 0.23% (1 case) | |
| Uterine | 9.07% of 529 cases | 7.18% (38 cases) | 1.89% (10 cases) | |||
| Lung adeno | 7.77% of 566 cases | 3.71% (21 cases) | 3.89% (22 cases) | 0.18% (1 case) | ||
| Esophagus | 7.69% of 182 cases | 4.95% (9 cases) | 2.75% (5 cases) | |||
| Melanoma | 7.21% of 444 cases | 6.08% (27 cases) | 1.13% (5 cases) | |||
| Pancreas | 7.07% of 184 cases | 4.89% (9 cases) | 0.54% (1 case) | 1.63% (3 cases) | ||
| Sarcoma | 7.06% of 255 cases | 1.57% (4 cases) | 5.49% (14 cases) | |||
| Uterine CS | 7.02% of 57 cases | 3.51% (2 cases) | 3.51% (2 cases) | |||
| ACC | 6.59% of 91 cases | 5.49% (5 cases) | 1.1% (1 case) | |||
| BICB | 6.18% of 1084 cases | 1.01% (11 cases) | 0.37% (4 cases) | 4.61% (50 cases) | 0.18% (2 cases) | |
| Ovarian | 5.14% of 584 cases | 0.86% (5 cases) | 0.17% (1 case) | 3.94% (23 cases) | 0.17% (1 case) | |
| Cervical | 4.38% of 297 cases | 3.03% (9 cases) | 0.34% (1 case) | 1.01% (3 cases) | ||
| Bladder | 3.41% of 411 cases | 2.68% (11 cases) | 0.49% (2 cases) | 0.24% (1 case) | ||
| Head & Neck | 2.68% of 523 cases | 2.49% (13 cases) | 0.19% (1 case) | |||
| Lung squ | 2.46% of 487 cases | 1.85% (9 cases) | 0.21% (1 case) | 0.21% (1 case) | 0.21% (1 case) | |
| Liver | 2.42% of 372 cases | 1.34% (5 cases) | 1.08% (4 cases) | |||
| PCPG | 1.69% of 178 cases | 1.12% (2 cases) | 0.56% (1 case) | |||
| Thyroid | 1.2% of 500 cases | 0.8% (4 cases) | 0.4% (2 cases) | |||
| Mesothelioma | 1.15% of 87 cases | 1.15% (1 case) | ||||
| pRCC | 1.06% of 283 cases | 1.06% (3 cases) | ||||
| Prostate | 0.81% of 494 cases | 0.61% (3 cases) | 0.2% (1 case) | |||
| Testicular germ cell | 0.67% of 149 cases | 0.67% (1 case) | ||||
| ccRCC | 0.59% of 511 cases | 0.59% (3 cases) | ||||
| LGG | 0.58% of 514 cases | 0.19% (1 case) | 0.39% (2 cases) | |||
| GBM | 0.51% of 592 cases | 0.51% (3 cases) | ||||
| AML | 0.5% of 200 cases | 0.5% (1 case) | ||||
| Cholangiocarcinoma | ||||||
| DLBC | ||||||
| Kidney Chromophobe | ||||||
| Thymoma | ||||||
| Uveal melanoma | ||||||
| GNAQ | ||||||
| Alteration | Mutation | Fusion | Amplification | Deep deletion | Multiple Alterations | |
| Uveal melanoma | 50% of 80 cases | 50% (40 cases) | ||||
| Uterine | 3.97% of 529 cases | 2.84% (15 cases) | 0.38% (2 cases) | 0.76% (4 cases) | ||
| Melanoma | 3.38% of 444 cases | 3.38% (15 cases) | ||||
| Stomach | 2.5% of 440 cases | 0.91% (4 cases) | 0.23% (1 case) | 1.36% (6 cases) | ||
| Esophagus | 2.2% of 182 cases | 0.55% (1 case) | 0.55% (1 case) | 0.55% (1 case) | 0.55% (1 case) | |
| DLBC | 2.08% of 48 cases | 2.08% (1 case) | ||||
| Bladder | 1.95% of 411 cases | 0.73% (3 cases) | 0.24% (1 case) | 0.97% (4 cases) | ||
| Uterine CS | 1.75% of 57 cases | 1.75% (1 case) | ||||
| Sarcoma | 1.57% of 255 cases | 1.57% (4 cases) | ||||
| Colorectal | 1.52% of 594 cases | 1.35% (8 cases) | 0.17% (1 case) | |||
| Lung adeno | 1.41% of 566 cases | 0.88% (5 cases) | 0.53% (3 cases) | |||
| Ovarian | 1.37% of 584 cases | 0.68% (4 cases) | 0.68% (4 cases) | |||
| ACC | 1.1% of 91 cases | 1.1% (1 case) | ||||
| Pancreas | 1.09% of 184 cases | 0.54% (1 case) | 0.54% (1 case) | |||
| GBM | 1.01% of 592 cases | 0.17% (1 case) | 0.68% (4 cases) | 0.17% (1 case) | ||
| Cervical | 1.01% of 297 cases | 0.67% (2 cases) | 0.34% (1 case) | |||
| BICB | 1.01% of 1084 cases | 0.28% (3 cases) | 0.09% (1 case) | 0.18% (2 cases) | 0.37% (4 cases) | 0.09% (1 case) |
| Lung squ | 0.82% of 487 cases | 0.41% (2 cases) | 0.41% (2 cases) | |||
| Liver | 0.81% of 372 cases | 0.27% (1 case) | 0.27% (1 case) | 0.27% (1 case) | ||
| Thymoma | 0.81% of 123 cases | 0.81% (1 case) | ||||
| Head & Neck | 0.76% of 523 cases | 0.38% (2 cases) | 0.38% (2 cases) | |||
| Testicular germ cell | 0.67% of 149 cases | 0.67% (1 case) | ||||
| PCPG | 0.56% of 178 cases | 0.56% (1 case) | ||||
| AML | 0.5% of 200 cases | 0.5% (1 case) | ||||
| pRCC | 0.35% of 283 cases | 0.35% (1 case) | ||||
| Thyroid | 0.2% of 500 cases | 0.2% (1 case) | ||||
| Prostate | 0.4% (2 cases) | |||||
| LGG | ||||||
| Cholangiocarcinoma | ||||||
| Kidney Chromophobe | ||||||
| ccRCC | ||||||
| Mesothelioma | ||||||
| GNA11 | ||||||
| Alteration | Mutation | Fusion | Amplification | Deep deletion | Multiple Alterations | |
| Uveal melanoma | 46.25 % of 80 cases | 45% (36 cases) | 1.25% (1 case) | |||
| Sarcoma | 5.88% of 255 cases | 0.39% (1 case) | 0.39% (1 case) | 3.53% (9 cases) | 1.57% (4 cases) | |
| Cervical | 4.71% of 297 cases | 1.01% (3 cases) | 1.35% (4 cases) | 2.36% (7 cases) | ||
| Melanoma | 4.05% of 444 cases | 3.83% (17 cases) | 0.23% (1 case | |||
| Esophagus | 3.3% of 182 cases | 1.1% (2 cases) | 2.2% (4 cases) | |||
| Ovarian | 2.91% of 584 cases | 0.51% (3 cases) | 2.4% (14 cases) | |||
| Uterine | 2.84% of 529 cases | 1.89% (10 cases) | 0.95% (5 cases) | |||
| LGG | 2.33% of 514 cases | 0.19% (1 case) | 2.14% (11 cases) | |||
| Lung adeno | 1.59% of 566 cases | 0.71% (4 cases) | 0.18% (1 case) | 0.71% (4 cases) | ||
| Colorectal | 1.52% of 594 cases | 1.01% (6 cases) | 0.51% (3 cases) | |||
| Bladder | 1.46% of 411 cases | 0.73% (3 cases) | 0.73% (3 cases) | |||
| BICB | 1.29% of 1084 cases | 0.46% (5 cases) | 0.18% (2 cases) | 0.65% (7 cases) | ||
| Prostate | 1.21% of 494 cases | 0.2% (1 case) | 0.2% (1 case) | 0.81% (4 cases) | ||
| GBM | 1.18% of 592 cases | 0.17% (1 case) | 0.84% (5 cases) | 0.17% (1 case) | ||
| Mesothelioma | 1.15% of 87 cases | 1.15% (1 case) | ||||
| PCPG | 1.12% of 178 cases | 1.12% (2 cases) | ||||
| Pancreas | 1.09% of 184 cases | 0.54% (1 case) | 0.54% (1 case) | |||
| Liver | 0.81% of 372 cases | 0.27% (1 case) | 0.54% (2 cases) | |||
| Thymoma | 0.81% of 123 cases | 0.81% (1 case) | ||||
| Head & Neck | 0.57% of 523 cases | 0.38% (2 cases) | 0.19% (1 case) | |||
| AML | 0.5% of 200 cases | 0.5% (1 case) | ||||
| Lung squ | 0.41% of 487 cases | 0.21% (1 case) | 0.21% (1 case) | |||
| ccRCC | 0.39% of 511 cases | 0.39% (2 cases) | ||||
| ACC | ||||||
| Cholangiocarcinoma | ||||||
| DLBC | ||||||
| Kidney Chromophobe | ||||||
| pRCC | ||||||
| Stomach | ||||||
| Testicular germ cell | ||||||
| Thyroid | ||||||
| Uterine CS | ||||||
Data were obtained in cBioportal from the studies TCGA PANCAN2018 (cerami et al. 2012; gao et al. 2013) [12,24]. AML: Acute Myeloid Leukemia, ACC: Adrenocortical Carcinoma, LGG: Brain Lower Grade Glioma, DLBC: Diffuse Large B-Cell Lymphoma, GBM: Glioblastoma Multiforme, ccRCC: Kidney Renal Clear Cell Carcinoma, pRCC: Kidney Renal Papillary Cell Carcinoma, PCPG: Pheochromocytoma and Paraganglioma, BICB: Breast Invasive Carcinoma Breast.